Wonderful Life: An Interview with Herb Boyer by Gitschier, Jane
Interview
Wonderful Life: An Interview with Herb Boyer
Jane Gitschier*
Departments of Medicine and Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, California, United States of America
Once upon a time, not so very long ago,
before restriction enzymes were ordered
from a New England Biolabs catalog and
vectors arrived in neat packages from
Promega, and before molecular biologists
added patents or a company to their CV,
there was Herb Boyer. One can almost
define the revolution in molecular genetics
by Herb’s story alone—the discovery of
the iconic restriction enzyme EcoR1 and
the definition of its sticky ends, the
collaboration with Stan Cohen that pro-
duced recombinant DNA, and the genesis
of the enduring gold standard in biotech-
nology, Genentech.
I had been fascinated by Herb’s story for
many years,as I myselfhad the good fortune
to do a post-doc at Genentech in the early
1980s. Much has been written about Herb
Boyer (Image 1), so I chose not to talk with
him about his role in the founding of
Genentech in 1976, nor the landmark
Boyer-Cohen patent, nor the mid-1970s
moratoriumonrecombinantDNAresearch.
Instead, I was interested in what came
before all of that—how Herb developed as a
scientist, how he become interested in
restriction enzymes and in vitro recombina-
tion—and by what came later. I’m sure
you’ll agree, this is equally rich reading.
Gitschier: I know you grew up in the
little town of Derry, Pennsylvania. What
role do you think your upbringing played
in some of the choices you made in your
life?
Boyer: My mother graduated from
high school, and she immediately married
my father at the age of 18. My dad was 12
years older than she. My dad left school
after the 8th grade and went to work. He
came from a large family with six siblings.
He was the oldest boy, so the story was he
quit school to help support his family.
I’m trying to write my memoirs now, so
I’ve been thinking a lot about my early
childhood. My upbringing was in a town
of about 3,000 people and the principal
industries were the railroad and a Wes-
tinghouse manufacturing facility. I went to
a small school, only 32 in my graduating
class, and I loved sports and the outdoors.
I used to hunt and fish with my father.
Gitschier: Where did your father
work?
Boyer: He worked for the Pennsylva-
nia Railroad. My father never owned a
car, never had a driver’s license. He’d walk
to work at the dispatch station, which was
about a hundred yards away from our
house. He was a brakeman on the freight
trains and would live on a caboose for a
couple of days at a time. I always thought
that was rather romantic. He worked in
terrible winter weather and stifling sum-
mer heat. By the time he retired, at age 72,
he was a conductor, and at that point he
was making $12,500 a year. That was my
starting salary at UCSF [University of
California San Francisco].
High school for me was football,
basketball, baseball, girls, hunting, and
fishing. And I worked at odd jobs. I dug
ditches, mowed lawns for 50 cents, painted
houses, distributed door-to-door advertise-
ments, and of course I was a newspaper
boy.
Gitschier: Was your father encourag-
ing about your staying in school and going
to college?
Boyer: I can never remember getting
encouragement from my mother or father
to go beyond a high school education,
though they weren’t opposed to it. I just
knew I had to get out of Derry, and that
was the only way I knew how to do it!
Gitschier: Your father lived at least 10
years after you became an assistant
professor at UCSF.
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Image 1. Herb Boyer.
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died.
Gitschier: So, he watched this incred-
ible progression in your life. What was that
like for you and for him?
Boyer: I’m not sure he had much of an
appreciation for what I did.
Gitschier: Did he ask you about it?
Boyer: Not a lot. He was a very quiet
man. My dad was just happy I didn’t turn
out to be a ne’er-do-well. I had a job and I
had kept it for a few years and that was
good enough for him.
But Jane, how could my parents relate
to this? They didn’t know what science
was or anything about experimental pro-
cedures. This is true of many people today,
even with substantial educational back-
grounds.
Gitschier: Let’s shift gears. I’d like to
talk to you about restriction and modifi-
cation.
Boyer: Four or five years ago, Stan
[Cohen] and I received the Sir Run Run
Shaw Prize in Hong Kong. In my
acceptance speech, I recounted some
history of restriction and modification
and all the little threads that appear to
have twisted my career—binary events
that seem improbable to have happened.
If this event didn’t happen, what would
have happened? But it happened, so you
go to another event. What is that movie
with Jimmy Stewart where he’s about to
throw himself off the bridge?
Gitschier: ‘‘It’s a Wonderful Life.’’
Boyer: It’s sort of like that—I can give
you a few examples. I went to a Benedic-
tine college and I took an elective
physiology course taught by Father Joel.
We had a brand new, shiny textbook with
a blue and white cover. Each of us was
assigned a chapter, and we had to give a
seminar on it. Which one did I get? ‘‘The
Structure of DNA.’’ This was 1957, and
the buzz of DNA was just getting into the
textbooks. And I had this fascination with
genetics—classical genetics—Drosophila,
corn, and bacteriology. I was really taken
with the Watson-Crick structure of DNA
and this started my fascination with the
heuristic value of the structure.
Then I had to decide what to do. I went
to the University of Pittsburgh Medical
School for an interview with this tough old
biochemist. And he said, ‘‘Well, if you get
into medical school, how are you going to
pay for it?’’ And I looked at him and I
said, ‘‘You mean I have to pay for it?’’
But I didn’t get in, which was hard on
my ego.
Gitschier: So there is binary point
number one.
Boyer: You see! My grades were not
that terrific, but remember that was before
grade inflation. I got a D in metaphysics,
and that didn’t help! I was taking a liberal
arts program. I got A’s in math, logic, etc.,
but all that other stuff—Chaucer—ouhhh.
Someone suggested going to grad school
for a couple of years, improving my
grades, and reapplying to medical school.
So, I arrived at the University of
Pittsburgh at the same time as a professor
studying bacterial genetics and gene reg-
ulation—Ellis Engelsberg. This is 1958.
You know, in 1958 the genetic code wasn’t
known, and nobody knew anything about
messenger RNA, and protein synthesis
was still speculative. If you think about
what has happened in 50 years—it’s
unbelievable.
Anyhow, I get singled out because I’m a
new graduate student with an interest in
bacterial genetics. So I get a chance to
work in Engelsberg’s lab on the genetic
control of the L-arabinose metabolic
pathway in E. coli. Ellis had recruited
Roger Weinberg as an assistant professor
and collaborator. Roger had found an L-
arabinose mutant defective for the epim-
erase enzyme. In the presence of L-
arabinose, the cell accumulates phosphor-
ylated ribulose, which inhibits growth of
the cell. So it’s an easy way to select for
mutants in all the preceding genes of the
pathway.
So Roger Weinberg decides that this
should be my project! I had to select
mutants induced by mutagens that theo-
retically could induce specific base pair
changes in the DNA. This could be
challenged by reversion of the mutation
with another mutagen to wild type. After
mapping the mutations and then doing
amino acid substitution analyses, we
would solve the genetic code, the Holy
Grail of genetics!!!
That was the plan! What the hell was I
thinking? Why didn’t I challenge these
guys?
The project required that I map arab-
inose mutants by the most inefficient way
to do recombination that you can ever
imagine—P1 phage transduction. At a low
frequency, the phage can incorporate
small fragments of DNA that when
injected into a cell can lead to recombi-
nation with the cellular chromosome.
Anyway, if you get yields of 10
9 phage
per ml you were doing well, and the
frequency of recombination is maybe one
in a thousand.
So, I started mapping a limited region
of an arabinose gene, doing forward and
reverse mutational analyses, and I was
getting worried, ‘‘Am I ever going to get
out of here?’’ But, even before I got too far
along on this project, the genetic code is
cracked by biochemical means! What a
blow! But I continued on with the project
for some reason I can’t remember.
I did decide on my own, though, that P1
transduction was not the way to do fine
structure mapping. In those days it didn’t
take too much to know the literature, and I
knew the literature cold. I was familiar
with all the latest work on Hfrs and
sexuality in bacteria, so I felt this system
[bacterial conjugation] would provide
higher recombination frequencies. So I
wrote to Ed Adelberg at Yale and asked
him if he would send me a couple of Hfr
strains. And Ed, being such a super guy,
sent them right away.
I started doing the crosses. The strain I
had been using was E. coli B/r. The Hfr
strains, of course, were K12s, so I had to
start by asking whether K12 would
actually mate with the B/r—no one had
ever done it before. I started out by
crossing Hfr K12 to the B/r strain and
comparing that with K12 to K12, as a
standard. I found there was a substantial
reduction in frequency of recombination
[in the K12 to B/r strain], and the linkage
of the various genes was also reduced.
So I started to do some backcrosses and
I found out that some progeny of the cross
did not exhibit these anomalous genetic
results. I mapped the alleles to a region
near the arabinose operon. Coincidence!
Gitschier: Did you publish that result?
Boyer: No, not at that time. I managed
to write an acceptable Ph.D. dissertation
with the other data. However, by that time
I was very interested in trying to explain
my observation and became more in-
trigued with plasmids, conjugation, and
bacterial sexuality. Ed Adelberg had
written a book and papers and reviews
on these subjects. So I wrote to Ed and
applied for a postdoctoral fellowship with
him, and he said, ‘‘Yeah, come on!’’
Gitschier: Did Ed know about your
results about K12 and B/r?
Boyer: Not at the time, but upon
arrival in his lab I described my results and
he encouraged me to continue my exper-
iments as well as a couple of other projects
he suggested. But my heart was in trying to
explain my observations.
Ed had a fairly small and close-knit
group and we would work in the evenings
and chat. Not long before I arrived,
Werner Arber and Daisy Dussoix demon-
strated that the restriction and modifica-
tion of DNA, a relatively ignored bacterial
phenomonology used for typing clinical
bacterial strains, was associated with
methylation of DNA and a site-specific
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graduate student in the lab, Noel Bouck,
and I were discussing the paper and she
said, ‘‘I really think that the anomalies
you’re seeing are due to the same thing.’’
So I took out the stains in which I had
changed the specificities, and did the
lambda phage restriction analyses. And
boom, boom, boom, it just lined up. I had
mapped the restriction and modification
alleles of E. coli K12 and B.
I became interested in pursuing it
further because of the predicted enzymatic
specificity. There were maybe three labo-
ratories in the world working on restriction
and modification at that time. I wanted to
purify and characterize these enzymes
because I thought it would be a great
way to study site-specific interactions
between proteins and DNA. Unlike re-
pressors, restriction and modification en-
zymes involved two proteins [the endonu-
clease and the methylase] that have to
recognize the same sequence, and I
thought that it would be pretty cool to
have two different ways of looking at it.
So, the last year at Yale, I experimented
with some way to assay for the K12 and B
restriction enzymes. And then I headed to
California [UCSF] where we finally settled
on an assay based on the sedimentation
coefficient of radioactive lambda DNA
[sigh!]. This is pre-gels—what a mess! We
had a 6-hour run, and we’d do three runs
a day. You’d take the little centrifuge
tubes, punch them at the bottom, collect
the contents drop-by-drop on little squares
of filter paper hung on a pin on a piece of
styrofoam, dry the papers, and put them
into the scintillation counter. It was SO
bad. And we couldn’t find any activity at
all!
Then Matt Meselsohn and Bob Yuan at
Harvard—I can’t remember the ratio-
nale—they threw S-adenosyl methionine
and ATP into the reaction and got
activity! So we did that, too, and we
started purifying those enzymes.
Gitschier: What year roughly are we?
Boyer: The period of 1966–1969. We
went on to purify the B restriction
endonuclease and began experiments to
determine the sequence at the cleavage
site, which we assumed would be the
recognition site. So we kept labeling the 59
end of cleaved DNA molecules and we
always ended up with equal mixtures of
four nucleotides. We never even thought
that there would be an endonuclease that
would bind at a specific site and then
move! I was so disappointed.
Gitschier: But at some point, you
make a switch, and you start working on a
different restriction enzyme.
Boyer: Well, here comes one of the
most bizarre little binary points in life! We
found out that these [Type I] endonucle-
ases aren’t cutting at a unique site. We
used a small phage DNA intermediate and
cleaved it with the B endonuclease. By
sedimentation analysis it looked like it had
a molecular weight of a linear fragment,
and that was what threw us off.
Gitschier: Why?
Boyer: Well, we thought it had one
site, and you assume it is always cleaving
at the same site! Apparently it was
cleaving, on average, one site, but not
the recognition site. Stu Linn at Berkeley
demonstrated, by electron microscopy,
that what appeared to be linear products
of the B endonuclease could be [denatured
and] reannealed as circular molecules.
So I thought, this is it! This is the end.
We’re not going to be able to determine
the [recognition] site with the technology
available at the time.
But there was literature, mainly from
Japan, demonstrating that bacteria carry-
ing drug resistance factors often had genes
for the restriction and modification of
DNA with different specificities. So we
decided to investigate these enzymes. I had
a graduate student who had a degree in
clinical microbiology and had experience
working in a hospital medical microbiol-
ogy lab, a wonderful guy named Bob
Yoshimori.
I asked Bob to go to the clinical lab at
the UCSF hospital and get a slew of
multiple drug-resistant E. coli. He came
back with 36 or so E. coli isolates that had
multiple drug resistance. And of those, we
found eight or ten with restriction and
modification activity as determined by
phage specificity analyses. We transferred
the plasmids into our K12 strains [restric-
tion mutants]. Most of the specificities
were like the one that had been reported
previously, namely RII [named after the
RII plasmid], but we found one that was
unique, and that was EcoRI.
We found out later that the EcoRI
plasmid came from a woman who was
admitted to the hospital with an E. coli
urinary tract infection that was resistant to
multiple antibiotics. Now, the RI endonu-
clease was never found anywhere else for
15 years, and then it was found in a
freshwater microorganism. It just had the
same specificity as RI.
Gitschier: Wow, you should write her
a thank you note.
Boyer: Well, I wish I had her name.
But how would I explain this to her? She’s
probably not even alive today.
Gitschier: And it could backfire. She
could sue!
Boyer: Well, I’ve thought of that too!
Gitschier: OK, you’ve got EcoRII
and EcoRI.
Boyer: We purified the restriction and
modification enzymes of both specificities.
We were so thrilled with the first centri-
fugation experiments. We digested lambda
DNA and we had these clear-cut separa-
tions of fragments in the sedimentation
analysis. And the patterns were different
from each other. We went on to determine
the sequence of the cleaved and methyl-
ated sites of the RI and RII enzymes. This
gave us a belated sense of achievement
given our prior experiments.
Gitschier: Was it the Haemophilus
influenza work that was going on around
the same time that made you think there
might be some enzymes out there for
which you could find a cleavage site?
Boyer: We knew about the work of
Ham Smith and Dan Nathans. And that
was SO frustrating because there they got
that sequence and we had been working
for at least a year! By that time Howard
Goodman had come to UCSF. He had
experience sequencing RNA molecules,
and so we naturally started a collaboration
on the sequence of the cleaved and
methylated sites. At that point, we knew
that RI didn’t cleave as frequently as all of
the other enzymes.
And then Paul Berg called. He had
heard about this enzyme and wanted to
know if he could get some. I said, ‘‘Sure.’’
Bob gave someone from his lab enough
enzyme to last a lifetime, and Berg gave it
to a couple of his post-docs and graduate
students. And it was actually Janet Mertz
and Ron Davis, an assistant professor at
Stanford, who cleaved SV40 with EcoRI
and then looked at it under an electron
microscope. They found that the cleaved
DNA would circularize at low tempera-
tures, and that’s the first evidence for the
enzyme generating cohesive ends.
Paul told us this while we were working
on the sequence of the cleaved end. We
already knew the 59 nucleotide, so I went
to Mike Bishop and said, ‘‘Mike, we need
some reverse transcriptase,’’ and we filled
in the single-stranded part of the end and
got the sequence overnight. It was another
eureka moment! There was a young
medical student [Judy Aldrich] working
on a summer research project and she and
I looked at the results the next morning, a
Saturday—it’s GAATTC!
Gitschier: So the RI sticky ends led
directly to in vitro recombination. Let’s
talk about how that took off.
Boyer: My own interest in recombina-
tion goes back to graduate school. It was
almost an article of faith that DNA would
PLoS Genetics | www.plosgenetics.org 3 September 2009 | Volume 5 | Issue 9 | e1000653break and exchange strands at any point
along the polynucleotide chain. I remem-
ber reading Dale Kaiser’s papers on the
cohesive ends of lambda, and musing
about restriction enzymes and Sanger’s
techniques for determining the sequences
of proteins with two-dimensional chroma-
tography. I was thinking if you could break
down DNA with these different enzymes,
given their specificities, you might be able
to separate smaller fragments and se-
quence them somehow.
I got an invitation to go to Hawaii
around 1971 for an East-West conference
on plasmids and drug-resistant factors.
Stanley Falkow was there—a great guy,
known him since my days at Yale. While
talking to Stan about our enzyme work, I
said, ‘‘Stan—you know those plasmids you
work with—we can take these things apart
and separate the fragments and maybe
look at where these resistance genes are.’’
And he says, ‘‘You go talk to Stan
Cohen—he’s interested in that.’’
So Stan Cohen and I get together and
learn of our mutual interests in plasmids
and in vitro recombination. He had just
described pSC101, which conferred resis-
tance to tetracycline, and we realized it
might be of significant value given its small
size. And just as importantly, he had
become aware of a scientist at the Univer-
sity of Hawaii who could transform E. coli
with DNA. It made all the difference in the
world to our thinking. So we agree that we
would see if we could cleave the pSC101
molecule with EcoRI and use it for a
collaborative recombination experiment.
Then another stroke of good luck. I was
scheduled to go to Cold Spring Harbor to
give a talk. I get picked up at the airport by
Joe Sambrook and Phil Sharp, and they
immediately take me into a darkroom
adjacent to their laboratory and show me
an agarose gel that had been run with
cleaved adenovirus DNA and stained with
ethidium bromide. It was one of the most
exciting things I could have looked at, and
I said, ‘‘Thank you, lord!’’ Because prior
to that, we’d have to analyze cleaved DNA
fragments by polyacrylamide gel analysis.
We would put the gel in a small metal tube
and then mechanically push it into a
guillotine-like device and slice small frag-
ments into scintillation vials. It would go
chop, chop, chop, and invariably pieces
would fly across the room and we’d be
down on the floor looking for slices. It was
like looking for a fallen contact lens. It was
so laborious and there was such variation
in the tritium counts. So I knew immedi-
ately that all the laborious work we had
done, we don’t have to do anymore!
We immediately found, using the Sam-
brook/Sharp technique, that pSC101 was
cleaved once with EcoRI. Stan sent the
DNA up, and we cleaved it and did the
ligation.
Gitschier: What was the other entity?
Boyer: Stan had another plasmid with
two different antibiotic resistance genes.
Annie Chang, Stan’s technician who lived
in San Francisco, transported the DNA
back and forth between our labs. Stan’s
lab would send us the plasmid DNA, we
would do the enzymatic treatments, Stan’s
lab would do the transformation and
selection, Annie would bring back the
plasmids, and we would analyze them by
cleavage and gel analysis of the fragments.
That was another eureka moment. Bob
Helling, a fellow graduate student of mine
from University of Pittsburgh who was
doing a sabbatical in my lab, and I went to
look at the gels in the darkroom, and there
it was. It actually brought tears to my eyes,
it was so exciting, and I knew what we had
done had a lot of potential.
Gitschier: What kind of potential?
Boyer: A lot of my mentors and
colleagues were leaving microbial systems
to study higher order cells, because
‘‘everything there was to know about
bacteria was known.’’ But they were
frustrated, because they had no hope to
isolate single genes or fragments of genes
from the chromosomes of ‘‘higher’’ organ-
isms. So when I looked at those gels, I
knew we’d be able to isolate any piece of
DNA that was cut with EcoRI, regardless
of where it came from.
Gitschier: I was just re-reading ‘‘In-
visible Frontiers’’ [about the race to clone
the human insulin gene, by Stephen S.
Hall].
Boyer: Great book.
Gitschier: Yes, and what I didn’t
appreciate was that October 14, 1980,
was the day Gilbert, Sanger, and Berg
won the Nobel prize AND the day
Genentech went public. That must have
been a very interesting day for you.
Boyer: Yeah. We were gathered at the
company to follow the reaction to our IPO
[initial public offering] and someone came
into the room with the morning [San
Francisco] Chronicle. And the headline was
‘‘Genentech Jolts Wall Street’’ and under-
neath is a photo of Paul Berg, ‘‘Berg Wins
Nobel Prize’’.
Gitschier: Many people have specu-
lated about why it is you and Stan Cohen
have never won a Nobel Prize, but I don’t
know that you’ve ever talked about that
publicly. Are you going to address this in
your memoir?
Boyer: I will, and I don’t mind talking
about it with you.
It is not for me to decide whether I
should orshouldnotwina NobelPrize.I’ve
received many prizes and honors and I am
indeedgratefulforthe recognition.Youcan
imagine from what I’ve said about my
boyhood, that I never would have expected
to do what I’ve done. I wanted to do
something important—I didn’t know what
it would be, butI planned to work hard and
see what I could do. I had no foresight that
this would be what it was.
Gitschier: When you say ‘‘that this
would be what it was’’, are you referring to
the scientific work, or are you referring to
Genentech?
Boyer: Both, I don’t separate them. I
don’t know how I could separate those two
events in my life.
Disappointed at times? Yeah. But I’ve
been through quite a few periods in my life
where I’ve had strong emotional reactions
to one thing or another. All of the
criticisms and rebuffs from colleagues that
came when I started Genentech, and prior
to that attacks on recombinant DNA
technology. One of the most difficult
periods for me was when my UCSF
colleagues were fairly critical; I was the
subject of an Academic Senate investiga-
tion. Gee, I thought what I was doing was
a pretty good thing, and you’d think I was
a criminal! That I found to be much more
difficult than not getting a Nobel Prize. All
in all, these experiences can be of great
value to your outlook on life.
I have been rewarded, and I am so
lucky, Jane. And I’m so grateful.
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